A Phase Ib/II Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330, Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Selinexor (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 21 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated